Category: Home

Anti-angiogenesis therapies for angiogenic diseases

Anti-angiogenesis therapies for angiogenic diseases

Current challenges of cancer anti-angiogenic therapy Freshly Squeezed Orange the cor of nanotherapeutics. Jpn J Cancer Res. Mao X, Xu J, Terapies W, Liang C, Hua J, Liu J, et al. A very interesting addition to the anti-angiogenesis drug arsenal can be achieved with the aim of nanotechnology, a novel but promising scientific field. A hypoxic microenvironment may also encourage tumor development, invasion, metastasis, immune evasion, and angiogenesis.

Video

Dr. Eng: Continuation of Anti-Angiogenesis Therapy

Anti-angiogenesis therapies for angiogenic diseases -

EMBO J. Fakhrejahani, E. Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials. Folberg, R. Vasculogenic mimicry. APMIS , — Fuchs, C. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma REGARD : an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Lancet , 31— Furuhashi, M. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate.

Cancer Res. Garon, E. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy REVEL : a multicentre, double-blind, randomised phase 3 trial.

Gilbert, M. A randomized trial of bevacizumab for newly diagnosed glioblastoma. Goel, S. Normalization of the vasculature for treatment of cancer and other diseases.

Greenberg, J. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature , — Grothey, A. Regorafenib monotheraphy for previously treated metastatic colorectal cancer CORRECT : an international, multicenter, randomized, placebo-controlled, phase 3 trial.

Gu, L. Regulation of XIAP translation and induction by MDM2 following irradiation. Hagglof, C. Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. PLoS ONE 5:e PubMed Abstract CrossRef Full Text. Harada, H. Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy.

Cancer , — Heist, R. Improved tumour vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Hendriksen, E. Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumourmodel.

Hernandez-Agudo, E. Monitoring vascular normalization induced by antiangiogenic treatment with 18F-fluoromisonidazole-PET. Hida, K. Tumour angiogenesis-characteristics of tumor endothelial cells. Hirschhaeuser, F. Lactate: a metabolic key player in cancer. Huang, Y. Vascular normalization as an emerging strategy to enhance cancer immunotherapy.

Hutson, T. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. Jain, R. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.

Jeong, H. Investigation of the lack of angiogenesis in the formation of lymph node metastases. Cancer Inst. Keunen, O. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Kilarski, W. Biomechanical regulation of blood vessel growth during tissue vascularization.

Kim, H. A domain responsible for HIF- 1alpha degradation by YC-1, a novel anticancer agent. PubMed Abstract Google Scholar. Kindler, H. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B CALGB Koch, C.

Optimizing hypoxia detection and treatment strategies. Koh, M. Molecular mechanisms for the activity of PX- , an antitumor inhibtor of the hypoxia-inducible factor-1alpha. Cancer Ther. Liang, W. Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses.

PLoS ONE 9:e Lo Dico, A. Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model.

Imaging 42, — Lu, K. Cancer Cell 22, 21— Lupo, G. An in vitro retinoblastoma human triple culture model of angiogenesis: a modulatory effect of TGF-β. Cancer Lett. Maes, H. Vesicular trafficking mechanisms in endothelial cells as modulators of the tumor vasculature and targets of antiangiogenic therapies.

FEBS J. Matsuda, K. Isolated tumor endothelial cells maintain specific character during long-term culture. McIntyre, A. Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. McMillin, D. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Drug Discov. Meijer, T. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Michaelson, M.

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. Miller, K. Can tumor angiogenesis be inhibited without resistance?

EXS 94, 95— Moeller, B. HIF-1 and tumour radiosensitivity. Cancer 95, 1—5. Nagy, J. Heterogeneity of the tumor vasculature: the need for new tumour blood vessel type-specific targets.

Metastasis 29, — Nanda, A. Tumor endothelial markers: new targets for cancer therapy. Nico, B. Intussusceptive microvascular growth in human glioma. Ohga, N. Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from high- and low-metastatic tumors.

Paulsson, J. Prognostic significance of stromal platelet- derived growth factor beta-receptor expression in human breast cancer. Powles, T. A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer.

Pujade-Lauraine, E. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. Rak, J. Rini, B. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

Russell, J. The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery. Salmeri, M. VEGF receptor-1 involvement in the pericyte loss induced by E. coli in an in vitro model of blood brain barrier. Saltz, L.

Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.

Sandler, A. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. Sattler, U. Glycolytic metabolism and tumour response to fractionated irradiation.

Schmidinger, M. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat. Seaman, S. Genes that distinguish physiological and pathological angiogenesis.

Tie-2 known as TEK is a commonly studied receptor that mediates the functions of angiopoietin. Ang-1 is a bifunctional protein and is mainly secreted by pericytes, smooth muscle cells, tumor cells, and others around endothelial cells to mediate vessel remodeling and vascular stabilization.

Ang-2 may exert pro- or anti-angiogenic activities in different environments based on dynamic concentrations of VEGF-A. Stimulated by VEGF-A, Ang-2 promotes angiogenesis and pericyte shedding to disturb vascular stability through competitively binding Tie-2 and integrin receptors.

However, under a low concentration of VEGF-A, Ang-2 induces apoptosis and vascular degeneration to inhibit tumor growth. Notch receptors are a kind of particular non-RTK proteins that engage in numerous cellular processes, like morphogenesis, proliferation, migration, differentiation, apoptosis, adhesion, EMT, and angiogenesis Fig.

Among the Notch family, Dll-4 and Jag-1 are the most representative ligands in tumor angiogenesis. Additionally, hypoxia is one of the causes of cancer metastasis, and the interaction between Dll-4 and HIF-1α significantly upregulates the expression of Dll-4 and aggravates hypoxia, promoting the aggressiveness of cancer cells.

The progression of various malignant tumors such as leukemia, BC, HCC, CC, and cholangiocarcinoma is highly linked to the over-expression of Jag For example, EphrinB2 is over-expressed in ovarian cancer, kidney cancer and melanoma, whereas EphrinA3 is up-regulated in squamous cell lung carcinoma SCLC and colon cancer.

Integrins are major adhesion factors in the extracellular matrix, which engage in various cellular processes in the human body by regulating signaling transduction between cells and of these cells with the surrounding matrix Fig.

Under the mediation of soluble ligands, extracellular matrix ECM , or cell surface bound ligands including growth factors, proteases, cytokines, structural constituents of the ECM like collagen and fibronectin , plasma proteins, microbial pathogens, or receptors specific to immune cells, integrin plays a pivotal role in cell homeostasis, immunity, inflammation, infection, thrombosis, lymphangiogenesis, angiogenesis, and tumorigenesis within the complex human internal environment.

In tumor angiogenesis, over-expressed α v integrins can be exploited by carcinomas to fight for vascular and stromal resources to encourage tumor progression and canceration. α v β6 integrin is the first adhesion factor among α v integrins shown to have angiogenic effects and is widely expressed on activated vascular ECs within remodeling and pathological tissues.

α v β 3 is an indispensable factor in angiogenesis initiated by bFGF and TNF-α signaling pathways, while α v β 5 is required for angiogenesis mediated by TGF-α and VEGF. For example, α 4 β 1 maintains the stability of endothelial cells and pericytes under the mediation of pro-angiogenic factors VEGF, bFGF, and TNF-α to support tumor angiogenesis.

Matrix metalloproteinases MMPs are a family of zinc- and calcium-dependent endopeptidases secreted by connective tissue and stromal cells, like fibroblast, ECs, macrophages, osteoblasts, lymphocytes and neutrophils Fig. All members within the MMPs family are precursor enzymes that require proteolysis to be effective, including collagenases, gelatinases, stromelysins, matrilysins, and MMP membrane-type MT -MMPs.

MMP-1 is an interstitial or fibroblast-type collagenase that degrades interstitial types I-III collagen, whereas MMP-7 is a matrilysin.

MMP-1 releases bFGF by degrading the basement membrane to induce tumor angiogenesis, while MMP-7 mediates ECs proliferation and up-regulates the expression of MMP-1 and MMP-2 to encourage tumor angiogenesis.

MMP-expressing stromal cells and functions of MMPs in tumor microenvironment. MMP precursors which are secreted by endothelial cells, fibroblasts, and lymphocytes et al. converted into active MMPs through enzymolysis. Subsequently, active MMPs participate in different biological processes including angiogenesis and tissue invasion by degrading specific extracellular matrix components.

Actually, the expression level of MMPs is maintained in a dynamic balance under the antagonism of endogenous tissue inhibitors of matrix metalloproteinases TIMP , a family of multifunctional proteins. In addition to stabilizing MMPs, TIMPs are involved in erythrocyte proliferation and cell growth, including soluble TIMP-1, TIMP-2, TIMP-4, and insoluble TIMP As a potent inhibitor of endogenous angiogenesis, angiostatin is a partial fragment of plasminogen that potently inhibits ECs proliferation.

In an intricate angiogenic system, almost all biomolecules act in interrelated manners to activate the proliferation, survival, migration, and morphogenesis of target cells to excite tumor angiogenesis. Apart from the factors above and downstream pathways shown in Fig. The specific roles and mechanisms of these biomolecules in angiogenesis and tumorigenesis will gradually be explored by researchers.

At present, this theory has been extended to various non-neoplastic diseases such as cardiovascular disease, rheumatoid arthritis RA , and diabetic retinopathy. The formation of new blood vessels has been observed since the earliest time, especially wound healing.

But this process has only ever been regarded as a simple pathological or physiological process unrelated to malignancies. In the s, some researchers have observed the development of blood vessels presents as a scattered pattern of branches, , and pathologist Virchow also described a rich vascular network in tumors in his Die Krankhaften Greschwulste.

Although this hypothesis attracted little scientific interest, Folkman persisted research and successfully cultured ECs in capillaries, which facilitated multiple classical angiogenic models, such as chick chorioallantoic membrane CAM and corneal transplantation models.

Until , Senger et al. discovered that vascular permeability could be enhanced by a substance derived from tumors named vascular permeability factor VPF , which was shown to have a strong angiogenic effect in subsequent scientific research, and was re-named as vascular endothelial growth factor VEGF.

and named as basic fibroblast growth factor bFGF. Followed by some major events in the field of angiogenesis: discovery to withdrawal of drugs such as TNP, the discovery of the anti-angiogenic effect of thalidomide, and the development of angiostatin and endostatin, the theory of tumor angiogenesis was generally accepted, and more researchers devoted to anti-angiogenic therapy.

In earlier studies, scientists believed that serious toxic effects and drug resistance would not develop in anti-angiogenic therapy because angiogenic inhibitors targeted genetically stable vascular ECs rather than tumor cells. Although some positive results were achieved, the clinical benefits did not meet expectations, the PFS rates of patients improved modestly, the improvement of OS rates were minimal, and even in some failed cases, it was observed that the toxicity suffered by the patients far more than the treatment effects.

For example, in November , the FDA withdrew the approval of bevacizumab Avastin ® for the treatment of HER2 negative metastatic BC based on four disappointing clinical trials: serious adverse events like hypertension and organ failure and minimal treatment benefits among BC patients treated with bevacizumab.

Although numerous perspectives and reflections rose in anti-angiogenic therapy, , proponents continued anti-angiogenic research and found that excessive limitation of angiogenesis not only affects the transportation of drugs but also exacerbates pathological manifestations of TME, inducing stronger hypoxic responses and aggressiveness of tumor, and eventually causing drug resistance or even cancer metastasis.

In the s, Rakesh K. As a result, the functional and morphological characterizations of the vessels are restored to a more normal condition, and the TME is more stable, finally improving drug transportation and delaying drug resistance and aggressiveness.

Li et al. comprehensively evaluated imaging methods that commonly used to detect vascular changes in tumor tissue. Zheng et al. suggested some promising strategies to optimize vascular normalization. The timeline of milestones regarding the research on tumor angiogenesis are shown in Fig.

Diagramatic illustrations of the relationship between tumor blood vessels, pro-angiogenic and anti-angiogenic factors. a Blood vessels with regularity and completeness depend on dynamic balance of pro-factors and anti- factors in normal tissues.

b Abnormal vessels with chaos, leakage and feeble blood circulation are caused by imbalance of mediators in tumor tissue. c Blood vessels are repaired through neutralizing abundant pro-factors or increasing anti-factors under the guidance of angiogenic inhibitors.

d Blood vessels in tumor tissue are destroyed by excessive inhibitors, which aggravates hypoxia within tumor tissue and hinders drug transportation. Anti-angiogenic therapy is achieved by inhibiting tumor growth and metastasis through anti-angiogenic drugs to limit the blood supply to tumor tissue.

Among them, recombinant monoclonal antibodies and small molecule tyrosine kinase inhibitors are the mainstream drugs used in anti-angiogenic treatment. Inhibitors approved for anti-angiogenic therapy are summarized in Table 1 , and potential agents evaluated in clinical trials are described in Table 2.

Monoclonal antibodies are derived from artificially prepared hybridoma cells, which have the advantages of high purity, high sensitivity, strong specificity, and less cross-reactivity.

When compared with kinase inhibitors, these immanent unique advantages in clinical treatment are comparatively beneficial to patients. The most representative antibody is bevacizumab Avastin ® Table 1.

In , anti-VEGF monoclonal antibody trials demonstrated that inhibitors targeting VEGF could decrease tumor growth, provoking scientists to investigate the clinical efficacy of bevacizumab.

Known as the first formal angiogenic inhibitor, bevacizumab is a macro-molecular recombinant human monoclonal antibody that obstructs the transduction of VEGF pathway by neutralizing all VEGF isoforms to inhibit tumor angiogenesis.

In addition to the first indication, bevacizumab has been approved for a variety of other cancers as monotherapy, as a surgical adjuvant, or in combination with chemotherapy, and more potential in anti-angiogenic therapy is being tested through clinical trials.

For example, the combination of bevacizumab, carboplatin, and paclitaxel or gemcitabine was approved by FDA for later treatment after bevacizumab monotherapy in platinum-sensitive recurrent epithelial ovarian cancer in placebo 3.

placebo 1. Furthermore, it prolonged the median OS 9. Additionally, the first-line therapy for metastatic CRC is a combination of ramucirumab and a modified FOLFOX-6 regimen mFOLFOX-6 , which demonstrated gratifying safety and efficacy in a phase II clinical trial NCT In a randomized ANNOUNCE clinical trial among patients, the addition of olaratumab did not significantly improve the OS rate doxorubicin plus olaratumab doxorubicin plus placebo Bevacizumab-awwb Mvasi ® is the first anti-tumor biosimilar of bevacizumab approved by FDA.

Ranibizumab is a prevalent anti-angiogenic agent in treating oculopathy Table 1. Oligonucleotides are nucleic acid polymers that regulates gene expression and have specially designed sequences, including antisense oligonucleotides ASOs , siRNA small interfering RNA , microRNA and aptamers.

Fusion proteins are complexes from binding the Fc segment of immunoglobulin to a biologically active functional protein molecule through genetic engineering technology.

Aflibercept Eylea ® is a recombinant decoy receptor targeted VEGF, which is combined of the extracellular VEGFR domain VEGFR-1 Ig2 region and VEGFR-2 Ig3 region and the Fc segment of human immunoglobulin G1 IgG1 and has long half-life in anti-angiogenesis Table 1.

Aflibercept inhibits the binding and activation of the VEGF family and natural VEGFR by specifically blocking VEGF-A and most proangiogenic cytokines, thereby inhibiting division and proliferation of ECs, reducing vascular permeability, and is commonly used in non-neoplastic angiogenic disease like AMD, DR, and DME.

It has been approved by FDA for the treatment of metastatic CRC patients who are resistant to or have progressed following an oxaliplatin-containing regimen. Everolimus RAD is an oral analog of rapamycin that inhibits proliferation and induces apoptosis and autophagy of tumor cells through indirectly blocked mTOR Table 1.

Thalidomide Thalomid ® was synthesized by the CIBA pharmaceutical company in and was initially used for mitigating morning sickness as a non-addictive and non-barbiturate tranquilizer Table 1. But the research on thalidomide was not terminated, in , thalidomide was approved for erythema nodosum leprosum ENL after a series of pharmacological studies.

Lenalidomide Revlimid ® was invented to reduce toxicity and enhance efficiency of thalidomide, which can specifically inhibit the growth of mature B cell lymphomas like MM and induce IL-2 release from T cells Table 1.

Since the first kinase inhibitor imatinib significantly reduced adverse events and improved the prognosis of patients with chronic myeloid leukemia CML in , the importance of kinases in tumorigenesis has attracted wide attention. Originally defined as a Raf inhibitor, sorafenib was obtained from a long period of high-throughput screening HTS and four-step structural modification.

As the first anti-angiogenic small molecule tyrosine kinase inhibitor, sorafenib remarkably promoted the subsequent development and clinical research of anti-angiogenic small molecule agents, in order to enhance the selectivity and efficacy of the drugs and reduce toxicity.

Regorafenib is a potent VEGFR-2 inhibitor with pyridine carboxamide derived from sorafenib structural modifications Table 1. Up to now, cabozantinib has been ratified for several most common angiogenic carcinomas NCT, NCT In recent years, research on highly selective targeted drugs has also made considerable progress in anti-angiogenic therapy Table 2.

Individual drugs have successfully passed preliminary clinical trials about the safety, tolerability and effectiveness of drugs, and entered into phase III or even phase IV clinical evaluation, such as bemarituzumab FPA , avapritinib and erdafitinib.

Bemarituzumab FPA is the first recombinant humanized IgG1 monoclonal antibody Table 2 , which obstructs ligand binding and downstream signaling activation by blocking the IgG III region of the FGFR-2b isoform.

Owing to this natural property of lacking the FUT8 gene, bemarituzumab can enhance antibody-independent cell-mediated cytotoxicity ADCC against tumor models with FGFR-2b over-expression. In the early phase I clinical trials NCT, NCT , the desirable safety, tolerance and pharmacokinetic characterization of bemarituzumab was demonstrated in gastrointestinal adenocarcinoma GEA and GC patients with FGFR-2b over-expression, leading to phase II clinical trial of bemarituzumab.

Avapritinib BLU is a selective and oral kinase inhibitor that targets PDGFR-α and c-Kit Table 2 , which has been approved by FDA for GIST, systemic mastocytosis, and solid tumors, especially for adult patients with metastatic or unresectable GIST carrying PDGFR-α 18 exon mutations.

The launch of avapritinib resulted in an unprecedented, durable clinical benefit to GIST patients with PDGFRA DV -mutation. The most common adverse events include nausea, vomiting, decreased appetite, diarrhea, fatigue, cognitive impairment, hair color changes, lacrimation, abdominal pain, constipation, rash, and dizziness.

The clinical potency of erdafitinib in NSCLC, lymphoma, cholangiocarcinoma, liver cancer, prostate cancer, esophageal cancer, or other carcinomas is undergoing investigation.

Common adverse events include hyponatremia, oral mucosal disease, and weakness, but no treatment-related deaths. Moreover, these FGFR inhibitors inhibits cell proliferation in FGFR-addicted cancer cells with FGFR aberrations such as gene amplification, activating mutations and chromosomal translocations.

In addition to the marketed and clinically evaluated anti-angiogenic drugs described previously, some novel TKIs have shown potent biological activity in the initial evaluation in kinase assay, which may be promising to become clinical candidates. Like compounds 23, 24 , and 25 , are selective inhibitors with good inhibitory activity targeted HIF-α.

TME is a highly complex ecosystem of cellular and noncellular components, which is broadly related to tumor invasion and recurrence. Angiogenic inhibitors used in cancer therapy by affecting the formation of new blood vessels in tumors, which have expended a new field for the treatment of a wide range of solid tumors.

However, there are still some shortcomings in anti-angiogenic therapy due to the complex mechanisms of tumor angiogenesis and limited research, including tumor relapse, drug resistance, , lack of bio-markers, short-acting efficacy, 27 , 28 and several serious adverse events.

It was initially assumed that anti-angiogenic therapy might not be toxic compared with other chemotherapeutic agents owing to genetic stability and quiescence of ECs under normal physiological conditions and the selectivity of targeted drugs. However, this was proved to be a miscalculation.

Common serious adverse events such as hypertension, proteinuria, lymphopenia, thrombocytopenia, leukopenia, neutropenia, and some physical abnormalities caused by different drugs have appeared in a number of different clinical treatments Table 1 , which may affect the tolerance of patients and even lead to treatment termination.

In addition, angiogenic inhibitors have a result on controlling growth and spread of tumor in the short term by blocking the blood supply which is manifested in clinical treatment as increased PFS , but the long-term result is an increased risk of tumor local invasion and distant metastasis induced by hypoxia, as well as the probability of revascularization and tumor resurgence after discontinuation of sustained treatment which manifests as an insignificant or even unchanged increase in OS.

Drug resistance is a dominant difficulty that consistently limits the clinical outcomes in targeted anti-angiogenic therapy, which can be divided into congenital resistance and acquired resistance Fig.

Acquired drug resistance has been comprehensively analyzed by researchers through cytological and molecular studies. These unique mechanisms include: a upregulation of compensatory pro-angiogenic signaling pathways in tumor tissue HGF, bFGF, VEGF-C, PlGF, angiopoietins, and Dll-4 have been widely testified that upregulated in various tumors with drug resistance ; , , b recruiting bone marrow-derived endothelial progenitor cells, pericyte progenitor cells, tumor-associated macrophages, and immature monocytic cells, which can maintain the formation of blood vessels; c recruitment of perivascular cells like pericytes , which can cover immature tumor blood vessels to prevent destruction by anti-angiogenic drugs; d unconventional angiogenic processes like vessel co-option, , , , vessel mimicry and intussusceptive angiogenesis.

Mechanisms of drug resistance in anti-angiogenic therapy. Some patients are intrinsically non-responsive to anti-angiogenic therapy while other patients who are initially responsive acquire adaptive resistance. The mechanisms that manifest acquired resistance to anti-angiogenic therapy include: compensatory upregulation of alternative pro-angiogenic factors such as bFGF, PDGF, and PlGF within the tumor; recruitment of bone marrow-derived endothelial progenitor cells to facilitate neovascularization; increased pericyte coverage protects tumor blood vessels; autophagy helps tumor cells thrive in a hypoxic environment; increased invasiveness of the tumor promotes the distant metastasis and invasion of tumor cells through blood and lymphatic circulation.

In addition, genetic mutations, vessel mimicry, vessel co-option, and intussusception angiogenesis also contribute to drug resistance. The application of biomarkers is a powerful adjuvant means which are essential for disease identification, early diagnosis and prevention, and drug treatment monitoring.

Biomarkers refer to biochemical indicators of normal physiological or pathogenic processes to furnish the structural or functional changes of systems, organs, tissues, cells and subcells, and can also be used for disease diagnosis, disease stage, or evaluating the safety and efficacy of a drug or regimen among targeted population.

For example, HER2 is a diagnostic indicator for breast cancer typing, and levels of PD-L1 is used to predict the efficacy of immune checkpoint inhibitors ICIs. Despite considerable efforts, there are few biomarkers responding to angiogenesis approved for clinical application.

With the advancement in bio-analytical technology and clinical bio-chemistry, tissue and cell concentrations of some angiogenic mediators, circulating ECs, circulating progenitor cells, CT imaging of blood flow and blood volume have been shown to have potential as biomarkers, but more clinical trials are needed to validate their prospective.

Developing efficient biomarkers for diagnosing the progression and stage of cancer and identifying mechanisms of tumor angiogenesis and drug resistance, in order to benefit drug selection, balance efficacy and toxicity, and simplify anti-cancer therapy.

Actually, due to numerous factors such as the complexity of tumor angiogenesis, heterogeneity and variability of tumors, the unpredictability of response or toxicity, and limitations of preclinical and clinical trials, the development of biomarkers will be a great challenge.

Since the first angiogenic inhibitor bevacizumab approved for treatment, combination therapy based on anti-angiogenic agents has infiltrated anti-tumor field.

Diversified methods in anti-cancer therapy provide more options for clinical treatment and make strong alliances possible. In recent several years, one of the prevalent research direction is the combination of angiogenic inhibitors and immune checkpoint inhibitors, in which better clinical benefits from HCC and RCC patients treated with programmed cell death 1 PD-1 and VEGFR-2 inhibitors than with monotherapy.

At the same time, it can neutralize excess VEGF, reconstruct the vascular system of tumor tissue, normalize vascular network, promote the blood transport of immunosuppressant, inhibit excessive angiogenesis, reduce microvascular density, and limit tumor growth, invasion and metastasis.

Some optimistic results of combination therapy have been achieved in recent years shown in Table 4. For example, in a phase III clinical trial NCT , the combination of bevacizumab with PD-1 inhibitor atezolizumab significantly improved the OS and PFS rates of unresectable HCC patients compared to sorafenib.

As mentioned before, although it has more damage to normal cells, blood vessels and immune system due to the administration with maximum tolerated dosage and poor tissue selectivity, chemotherapy is an irreplaceable method for many advanced patients with cancer metastasis to prolong the survival.

Some relevant clinical trials with positive outcomes have been shown in Table 4. For example, a phase III clinical trial NCT have shown that the addition of atezolizumab anti-PD-L1 greatly extended the OS Another notable therapeutic method is an emerging adjuvant strategy - neoadjuvant chemotherapy NACT , aiming to reduce the tumor and kill invisible metastatic tumor cells through systemic chemotherapy to facilitate subsequent surgery, radiotherapy, and other treatments.

Up to now, various NACT regimens SOX, XELOX, FOLFOX have been suggested with satisfactory clinical results in primary or advanced tumors and lower risk of progression, but some discouraging clinical evidence of NACT also observed in recent years especially breast cancer.

summarized a number of potential mechanisms of chemoresistance in NACT, wherein, it is reported that NACT could stimulate cancer metastasis through inducing angiogenesis, lymphangiogenesis and inflammatory infiltration, altering immune responses and worsening TME, and these changes may induce secondary chemoresistance.

Theoretically, it is promising, but massive efforts are also necessary, some clinical trials are already underway NCT, NCT, NCT, NCT, NCT Apart from the means above, exploiting novel selective multi-targeted kinase inhibitors is one of the current trendy research directions.

In tumor angiogenesis, various angiogenic tyrosine kinases act synergistically to induce an array of intracellular signaling cascades instead of working individually.

In normal tissue, anti-angiogenic molecules can balance the pro-angiogenic factors to maintain the homeostasis of the internal environment. The active angiogenesis in tumor tissue is related to the over-activation of pro-angiogenic factors and the over-inhibition of anti-angiogenic mediators.

Hence, endogenous anti-angiogenic components or their derivatives may be conducive to vascular normalization and therapeutic efficiency. Recombinant human endostatin is an angiogenic inhibitor with no cytotoxicity approved by the Chinese FDA for treating various cancers, including NSCLC.

Angiogenesis is one of the key conditions for the proliferation, invasion, and metastasis of carcinomas and anti-angiogenic treatment has gradually become a prevalent anti-tumor strategy with a criterion of vascular optimization.

But some common issues that cannot be ignored remain to be solved such as insufficient therapeutic efficacy, reproducibility and popularization of treatment modalities.

With an in-depth understanding of tumor angiogenesis, tumor microenvironment, and drug resistance, these problems may be solved in the near future.

As an emerging strategy, anti-angiogenic therapy will achieve more clinical benefits for cancer patients and anti-tumor therapy, and facilitate the clinical treatment of non-neoplastic angiogenesis-related diseases as well. Larionova, I.

New angiogenic regulators produced by TAMs: perspective for pargeting tumor angiogenesis. Cancers 13 , Article CAS PubMed PubMed Central Google Scholar. Duran, C. et al. Molecular regulation of sprouting angiogenesis. Article PubMed Google Scholar.

Teleanu, R. Tumor angiogenesis and anti-angiogenic strategies for cancer treatment. Article PubMed PubMed Central Google Scholar.

Folkman, J. Angiogenesis: an organizing principle for drug discovery? Drug Discov. Article CAS PubMed Google Scholar. Smolen, J. New therapies for treatment of rheumatoid arthritis.

Lancet , — Creamer, D. Costa, C. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 10 , — Caldwell, R. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives.

Diabetes Metab. Ng, E. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.

Khosravi Shahi, P. Tumoral angiogenesis and breast cancer. Zhong, M. TIPE regulates VEGFR2 expression and promotes angiogenesis in colorectal cancer.

Hall, R. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer NSCLC. Lung Cancer Res.

CAS PubMed PubMed Central Google Scholar. Zimna, A. Hypoxia-inducible factor-1 in physiological and pathophysiological angiogenesis: applications and therapies.

Conway, E. Molecular mechanisms of blood vessel growth. Kalluri, R. Basement membranes: structure, assembly and role in tumour angiogenesis. Cancer 3 , — Gasparini, G. Angiogenic inhibitors: a new therapeutic strategy in oncology. Article CAS Google Scholar. Adams, R. Molecular regulation of angiogenesis and lymphangiogenesis.

Cell Biol. Jain, R. Molecular regulation of vessel maturation. Rowley, D. What might a stromal response mean to prostate cancer progression? Cancer Metastasis Rev. Liakouli, V. The role of extracellular matrix components in angiogenesis and fibrosis: possible implication for Systemic Sclerosis.

Shiga, K. Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers 7 , — Roland, C.

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Cancer Ther.

Ribatti, D. Immune cells and angiogenesis. Med 13 , — Parmar, D. Angiopoietin inhibitors: a review on targeting tumor angiogenesis. Deyell, M. Cancer metastasis as a non-healing wound. Cancer , — Viallard, C.

Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis 20 , — Bellou, S. Anti-angiogenesis in cancer therapy: hercules and hydra. Cancer Lett. Ebos, J. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Pirker, R. Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer.

Biller, L. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA , Luqmani, Y. Mechanisms of drug resistance in cancer chemotherapy.

Saeki, T. Drug resistance in chemotherapy for breast cancer. Cancer Chemother. Salgia, R. Trends Cancer 4 , — Turner, N. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. Duesberg, P. Cancer drug resistance: the central role of the karyotype. Drug Resist. Lahiry, P.

Kinase mutations in human disease: interpreting genotype-phenotype relationships. Claesson-Welsh, L. Vascular permeability—the essentials. De Bock, K.

Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Mortezaee, K. Immune escape: a critical hallmark in solid tumors.

Life Sci. Igney, F. Immune escape of tumors: apoptosis resistance and tumor counterattack. Majidpoor, J. Angiogenesis as a hallmark of solid tumors—clinical perspectives.

Choi, S. Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer. Zhong, L. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct. Huinen, Z. Anti-angiogenic agents—overcoming tumour endothelial cell anergy and improving immunotherapy outcomes.

Gacche, R. Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy. Acta , — CAS PubMed Google Scholar. Bergers, G. Modes of resistance to anti-angiogenic therapy. Cancer 8 , — Ansari, M. Cancer combination therapies by angiogenesis inhibitors; a comprehensive review.

Cell Commun. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol. Carmeliet, P. Angiogenesis in cancer and other diseases.

Goel, S. Normalization of the vasculature for treatment of cancer and other diseases. Kim, C. Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption. Cancer Cell 25 , — Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.

Chauhan, V. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Martin, J. Normalizing function of tumor vessels: progress, opportunities, and challenges. Yang, T. Vascular normalization: a new window opened for cancer therapies.

Stylianopoulos, T. Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: from mathematical modeling to bench to bedside. The role of mechanical forces in tumor growth and therapy.

Combining two strategies to improve perfusion and drug delivery in solid tumors. Natl Acad. USA , — Delivering nanomedicine to solid tumors. Hamzah, J. Vascular normalization in Rgs5-deficient tumours promotes immune destruction.

Vaupel, P. Hypoxia in cancer: significance and impact on clinical outcome. Stubbs, M. Causes and consequences of tumour acidity and implications for treatment.

Today 6 , 15—19 Lee, E. Tumor pH-responsive flower-like micelles of poly l-lactic acid -b-poly ethylene glycol -b-poly l-histidine. Release , 19—26 Zhang, Z. Rational design of nanoparticles with deep tumor penetration for effective treatment of tumor metastasis.

Article Google Scholar. Khawar, I. Improving drug delivery to solid tumors: Priming the tumor microenvironment. Release , 78—89 Zhu, L. Angiogenesis and immune checkpoint dual blockade in combination with radiotherapy for treatment of solid cancers: opportunities and challenges.

Oncogenesis 10 , 47 Li, X. The immunological and metabolic landscape in primary and metastatic liver cancer. Cancer 21 , — Provenzano, P. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.

Cancer Cell 21 , — Milosevic, M. The human tumor microenvironment: invasive needle measurement of oxygen and interstitial fluid pressure. Chun, C. in Vascular Tumors and Developmental Malformations eds. North, P. Hillen, F. Tumour vascularization: sprouting angiogenesis and beyond.

Gianni-Barrera, R. Split for the cure: VEGF, PDGF-BB and intussusception in therapeutic angiogenesis. Burri, P. Intussusceptive angiogenesis—the alternative to capillary sprouting. Ratajska, A. Vasculogenesis and its cellular therapeutic applications.

Cells Tissues Organs , — Shi, L. As one of the key protein kinases controlling signal transduction from various growth factors and upstream proteins to the level of mRNA translation and ribosome biogenesis , mammalian target of rapamycin mTOR plays a critical role in regulating cell cycle progression, cellular proliferation and growth, and angiogenesis.

Temsirolimus is recommended as first-line treatment for patients with poor-prognosis metastatic RCC. In , the FDA approved everolimus Afinitor, also known as RAD as the second drug in the class of mTOR inhibitors for the treatment of advanced RCC after failure of treatment with sunitinib or sorafenib.

Interestingly, research on some of the previously approved chemotherapeutic agents, such as doxorubicin and cisplatin, demonstrates that they inhibit VEGF production. Thalidomide inhibits angiogenesis mediated by VEGF and bFGF, and studies have shown that thalidomide in combination with dexamethasone has increased the survival of multiple myeloma patients.

In addition to the chemotherapeutic and endogenous angiogenesis inhibitors, natural sources with antiangiogenic properties include tree bark, fungi, shark muscle and cartilage, sea coral, green tea, and herbs such as licorice, ginseng, cumin, and garlic.

In total, more than angiogenesis inhibitors have been discovered to date. Although they may not necessarily directly kill tumor cells, angiogenesis inhibitors significantly enhance the efficacy of standard chemotherapy and radiation therapy by inhibiting tumor growth and tumor metastasis.

Therefore, this type of therapy may need to be administered over a long period of time. Since antiangiogenesis therapy is a targeted therapy aimed specifically at the angiogenic stimulators and the angiogenic microvascular endothelial cells, antiangiogenesis therapy usually produces only mild side effects and is less toxic to most healthy cells.

But as angiogenesis is important in wound healing and reproduction, long-term treatment with antiangiogenic agents could cause problems with bleeding, blood clotting, heart function, the immune system, and the reproductive system, with some side effects still unknown.

Since the time when Dr. Folkman pioneered the concept of antiangiogenesis therapy for cancer treatment four decades ago, angiogenesis research has gained tremendous interest in both academic research institutions and the pharmaceutical industry.

Although hundreds of antiangiogenesis therapeutic agents are under investigation, the FDA currently has approved only 14 anticancer drugs with recognized antiangiogenic properties. Based on therapeutic targets, these agents can be grouped into four major categories: monoclonal antibody therapies, small-molecule RTK inhibitors, mTOR inhibitors, and unknown mechanisms.

Monoclonal Antibodies: These agents work by binding biologically active forms of angiogenic stimulators or their receptors and inhibiting endothelial cell proliferation and angiogenesis. Adverse effects of monoclonal antibody therapy are usually fairly mild.

Side effects can include fever, chills, weakness, headache, nausea, vomiting, diarrhea, low blood pressure, and rashes TABLE 1. Small-Molecule RTK Inhibitors: This is currently the largest class of drugs that block angiogenesis.

These agents have the advantages of hitting multiple targets, oral administration, and potential for lower cost. Lack of target specificity leads to unexpected toxicity but also promising efficacy. Hypertension, hemorrhage, and cavitation are common toxicities among this class of agents.

Rash, fatigue, myalgia, and hand-foot syndrome are more specifically seen with RTK inhibitors. A major adverse effect with the EGF RTK inhibitors is an acnelike rash TABLE 2.

mTOR Inhibitors: These agents represent a third, smaller category of antiangiogenic therapies with two FDA-approved agents, temsirolimus Torisel and everolimus Afinitor.

Other common adverse events for temsirolimus and everolimus include fatigue, stomatitis, diarrhea, hypophosphatemia, low red blood cells and platelets, and peripheral edema. These adverse events are commonly reversible upon treatment discontinuation.

Less common symptoms are renal insufficiency, interstitial pneumonitis, and low white blood cells TABLE 3. Unknown Mechanisms: Bortezomib Velcade and thalidomide Thalomid may indirectly inhibit angiogenesis through mechanisms that are not completely understood TABLE 4.

Antiangiogenesis therapy represents one of the most significant advances in clinical oncology. It has sparked tremendous interest in angiogenesis research in both academic research institutions and the pharmaceutical industry for the past two decades.

The FDA has approved 14 anticancer drugs with recognized antiangiogenic properties. More research is needed to fully understand the biological mechanisms of tumor angiogenesis to optimize this new cancer treatment strategy.

Next-generation medications are in development to increase the target specificity and to investigate possible treatments across the spectrum of solid tumors. Although the majority of the currently approved antiangiogenesis drugs only offer a modest survival benefit in a limited patient population, they have paved the way for the development of an optimized antiangiogenesis strategy and improved cancer treatments.

Nussenbaum F, Herman IM. Tumor angiogenesis: insights and innovations. J Oncol. Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J Invest Derm.

Tortora G, Melisi D, Ciardiello F. Angiogenesis: a target for cancer therapy. Curr Pharm Des. Fidler IJ, Lee ME. Neoplastic angiogenesis—not all blood vessels are created equal. N Engl J Med. Ma JX, Zhang SX, Wang JJ. Down-regulation of angiogenic inhibitors: a potential pathogenic mechanism for diabetic complications.

Curr Diabetes Rev. Zaman K, Driscoll R, Hahn D, et al. Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs.

conservative therapy. Int J Cancer. Pandya NM, Dhalla NS, Santani DD. Angiogenesis—a new target for future therapy. Vascul Pharmacol. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol. Semenza GL. A new weapon for attacking tumor blood vessels.

Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol.

Skip to Content. Anti-angiogenesis therapies for angiogenic diseases inhibitors are a type of cancer treatment. Viseases stop a process in the body called angiogenesis, or blood vessel formation. Angiogenesis is how the body forms new blood vessels. This is a normal part of growth and healing.

Anti-angiogenesis therapies for angiogenic diseases -

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.

Eur J Cancer. Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, et al. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non—small-cell lung cancer: a randomized, controlled phase III trial.

Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-carbonero R, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine RAISE : a randomised, double-blind, multicentre, phase 3 study.

Lancet Oncol. Maj E, Papiernik D, Wietrzyk J. Antiangiogenic cancer treatment: the great discovery and greater complexity review. Int J Oncol. Li J-L, Sainson RCA, Oon CE, Turley H, Leek R, Sheldon H, et al.

DLL4-notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Clarke JM, Hurwitz HI. Understanding and targeting resistance to anti-angiogenic therapies.

J Gastrointest Oncol. Balamurugan K. HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int J Cancer. Jeong W, Rapisarda A, Ryun S, Robert P, Chen A, Melillo G, et al.

Pilot trial of EZN, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha HIF-1α , in patients with refractory solid tumors. Cancer Chemother Pharmacol. Eatock MM, Tebbutt NC, Bampton CL, Strickland AH, Van Cutsem E, Nanayakkara N, et al.

Phase II randomized, double-blind, placebo-controlled study of AMG trebananib in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann Oncol. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al.

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to anti-Angiogenic therapy and development of third-generation anti-Angiogenic drug candidates. Genes Cancer.

Viallard C, Larrivee B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Shojaei F, Ferrara N. Drug Resist Updat. Orimo A, Gupta PB, Sgroi DC, Arenzana-seisdedos F, Delaunay T, Naeem R, et al.

Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science Article CAS Google Scholar. Zarrin B, Zarifi F, Vaseghi G, Javanmard SH.

Acquired tumor resistance to antiangiogenic therapy: mechanisms at a glance. J Res Med Sci. Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy. Cold Spring Harb Perspect Med. Article Google Scholar. Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy?

Article PubMed PubMed Central Google Scholar. Yasuda S, Sho M, Yamato I, Yoshiji H, Wakatsuki K, Nishiwada S, et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 VEGFR2 induces synergistic anti-tumour effectin vivo.

Clin Exp Immunol. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.

Hillan K, Koeppen K, Tobin P, Pham T. The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer MBC. Proc Am Soc Clin Oncol. Escudier B, Eisen T, Stadler WM, Szczylik C, Demkow T, Hutson TE, et al.

Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase iii treatment approaches in renal cancer global evaluation trial.

Reinmuth N, Thomas M, Meister M, Schnabel PA, Kreuter M. Current data on predictive markers for anti-angiogenic therapy in thoracic tumours. Eur Respir J. Kim C, Yang H, Fukushima Y, Saw PE, Lee J, Park JS, et al. Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption.

Martinetti A, Miceli R, Sottotetti E, Di Bartolomeo M, De Braud F, Gevorgyan A, et al. Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens.

Cancers Basel. Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-neblett KL, Martin A, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Sammarco G, Gallo G, Vescio G, Picciariello A, Paola DG, Trompetto M, et al.

Mast cells, micrornas and others: the role of translational research on colorectal cancer in the forthcoming era of precision medicine.

J Clin Med. Ammendola M, Sacco R, Sammarco G, Luposella M, Patruno R, Gadaleta COD, et al. Mast cell-targeted strategies in cancer therapy. Transfus Med Hemother. Angelucci A, Di Padova M. Int J Mol Sci. Meert A-P, Paesmans M, Martin B, Delmotte P, Berghmans T, Verdebout J-M, et al.

The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with. Br J Cancer. Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, et al.

Impact of vascular endothelial growth factor-a expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.

Shiroishi MS, Boxerman JL, Pope WB. Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma. Vasudev NS, Reynolds AR.

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Rojas JD, Lin F, Chiang Y, Chytil A, Chong DC, Bautch VL, et al. Ultrasound molecular imaging of VEGFR-2 in clear-cell renal cell carcinoma tracks disease response to antiangiogenic and notch-inhibition therapy.

Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol. Touyz RM, Lang NN. Hypertension and antiangiogenesis the Janus face of VEGF inhibitors. JACC Cardio Oncol. Dobbin SJH, Cameron AC, Petrie MC, Jones RJ, Touyz RM, Lang NN.

Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. de la Torre P, Pérez-Lorenzo MJ, Alcázar-garrido Á, Flores AI. Cell-based nanoparticles delivery systems for targeted cancer therapy: lessons from anti-angiogenesis treatments.

Mukherjee S, Patra CR. Therapeutic application of anti-angiogenic nanomaterials in cancers. Liu H, Zhang Y, Zheng S, Weng Z, Ma J, Li Y, et al.

Biochemical and biophysical research communications detention of copper by sulfur nanoparticles inhibits the proliferation of A malignant melanoma and MCF-7 breast cancer cells.

Biochem Biophys Res Commun. Potdar PD, Shetti AU. Chitosan nanoparticles: an emerging weapon against the cancer. MOJ Cell Sci Rep. Trickler WJ, Nagvekar AA, Dash AK. A novel nanoparticle formulation for sustained paclitaxel delivery.

AAPS PharmSciTech. Download references. Nuffield Department of Population Health, University of Oxford, Oxford, UK. Institute of Cardiovascular Science, University College London, London, UK. Ayodipupo S. Department of Basic Science, Prince Sultan Bin Abdulaziz College for Emergency Medical Services, King Saud University, Riyadh, Saudi Arabia.

You can also search for this author in PubMed Google Scholar. ASO conceptualized the topic, designed the study methodology, conducted the literature search, and wrote the initial draft.

FA, MA, AA and MB conceptualized the topic, conducted the literature search and contributed to the initial draft. The authors read and approved the final draft of the manuscript and take responsibility for this paper. Correspondence to Ayodipupo S. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.

If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

Reprints and permissions. Oguntade, A. et al. Anti-angiogenesis in cancer therapeutics: the magic bullet. J Egypt Natl Canc Inst 33 , 15 Download citation. Received : 18 November Accepted : 08 June Published : 02 July Anyone you share the following link with will be able to read this content:.

Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Skip to main content. Search all SpringerOpen articles Search. Download PDF. Narrative Review Open access Published: 02 July Anti-angiogenesis in cancer therapeutics: the magic bullet Ayodipupo S.

Oguntade ORCID: orcid. Abstract Background Angiogenesis is the formation of new vascular networks from preexisting ones through the migration and proliferation of differentiated endothelial cells. Main body of the abstract MEDLINE and EMBASE databases were searched for publications on antiangiogenic therapy in cancer therapeutics from to Short conclusion Clinical surveillance is important for the early detection of tumour resistance and treatment failure using reliable biomarkers.

Background Cancers still account for significant morbidity and mortality globally despite remarkable advances in the management of cancers [ 1 ].

Main text We searched MEDLINE and EMBASE for publications on anti-angiogenesis in cancer from to as part of a larger project on anti-angiogenesis and cancer therapeutics. Anti-angiogenics in cancers Several preclinical and clinical studies in cancer research have targeted different steps of the angiogenic pathway.

Table 1 Selected VEGF-targeted anti-angiogenics and their therapeutic indications Full size table. Clinical approach to cardiovascular toxicity of antiangiogenic therapy.

Full size image. Table 2 Different delivery methods for nanoparticles Full size table. Conclusion Anti-angiogenic therapy in cancers has enormous potentials using VEGF signaling pathways.

Availability of data and materials Not applicable. References GBD Disease and Injury Incidence and Prevalence Collaborators. Google Scholar Gupta K, Zhang J. Article CAS PubMed PubMed Central Google Scholar Kim KJ, Li B, Winer B, Armanini M, Gillett N, Philips HS, et al.

CAS Google Scholar Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Article CAS PubMed Google Scholar Planchard D, Planchard D. Article CAS PubMed Google Scholar Shih T, Lindley C. Article CAS PubMed Google Scholar Wilhelm SM, Carter C, Tang L, Wilkie D, Mcnabola A, Rong H, et al.

Article CAS PubMed Google Scholar Chase DM, Chaplin DJ, Monk BJ. Article CAS PubMed Google Scholar Kazazi-Hyseni F, Beijnen JH, Schellens JH. Article CAS PubMed PubMed Central Google Scholar Ferrara N, Kerbel RS.

Article CAS PubMed Google Scholar Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Article CAS PubMed Google Scholar Miles DW, Chan A, Dirix LY, Corte J. Article CAS PubMed Google Scholar Robert NJ, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, et al.

Article CAS PubMed Google Scholar Tabernero J, Van Cutsem E, Lakomy R, Prausova J, Ruff P, Prausova J, et al. Article CAS PubMed Google Scholar Ramlau R, Gorbunova V, Ciuleanu TE, Novello S, Ozguroglu M, Goksel T, et al.

Article CAS PubMed Google Scholar Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-carbonero R, et al. Article CAS PubMed Google Scholar Maj E, Papiernik D, Wietrzyk J. Chen HX, Cleck JN Adverse effects of anticancer agents that target the VEGF pathway.

Nat Rev Clin Oncol 6 8 — Hutson TE et al Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.

Oncologist 13 10 — Dienstmann R et al Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.

Oncologist 16 12 — Schuster C et al Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension.

PLoS ONE 7 6 :e Rini BI et al Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 9 — Osterlund P et al Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy.

Br J Cancer 4 — Mancuso MR et al Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 10 — Griffioen AW et al Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients.

Clin Cancer Res 18 14 — Wolter P et al Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. Acta Oncol 48 4 — Desar IM et al The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients.

A report of three cases. Acta Oncol 48 6 — Grothey A et al Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study BRiTE. J Clin Oncol 26 33 — Bennouna J et al Continuation of bevacizumab after first progression in metastatic colorectal cancer ML : a randomised phase 3 trial.

Lancet Oncol 14 1 — Rini BI et al Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27 27 — Rini BI et al Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

J Clin Oncol 26 22 — Di Lorenzo G et al Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. Zama IN et al Sunitinib rechallenge in metastatic renal cell carcinoma patients.

Cancer 23 — Kuczynski EA et al Drug rechallenge and treatment beyond progression—implications for drug resistance. Nat Rev Clin Oncol 10 10 — Tang TC et al Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.

Neoplasia 12 11 — Zhang L et al Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS ONE 6 4 :e Jayson GC, Hicklin DJ, Ellis LM Antiangiogenic therapy—evolving view based on clinical trial results.

Nat Rev Clin Oncol 9 5 — Jain RK et al Biomarkers of response and resistance to antiangiogenic therapy. Jubb AM, Harris AL Biomarkers to predict the clinical efficacy of bevacizumab in cancer.

Lancet Oncol 11 12 — Hegde PS et al Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res 19 4 — J Clin Oncol 31 14 — Miles DW et al Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

Br J Cancer 5 — Van Cutsem E et al Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. Tran HT et al Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.

Lancet Oncol 13 8 — Collinson F et al Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin Cancer Res 19 18 — Maru D, Venook AP, Ellis LM Predictive biomarkers for bevacizumab: are we there yet?

Clin Cancer Res 19 11 — Lambrechts D et al VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 13 7 — Beuselinck B, et al.

Acta Oncol 53 1 — Clin Cancer Res 18 24 — Hahn OM et al Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.

J Clin Oncol 26 28 — Flaherty KT et al Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 7 4 — Han KS et al Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy.

Cancer 10 — Fournier LS et al Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology 2 — Smith AD, et al. Urol Oncol 7 — Nathan PD et al CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.

Cancer Biol Ther 9 1 — van der Veldt AA et al Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Krajewski KM et al Comparison of four early posttherapy imaging changes EPTIC; RECIST 1. Eur Urol — Smith AD et al Morphology, Attenuation, Size, and Structure MASS criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.

AJR Am J Roentgenol 6 — Smith AD, Lieber ML, Shah SN Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.

AJR Am J Roentgenol 1 — Vasudev NS et al Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy. Chun YS et al Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.

JAMA 21 — Bergers G, Hanahan D Modes of resistance to anti-angiogenic therapy. Cancer Res 72 8 — Helfrich I et al Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.

J Exp Med 3 — Bergers G et al Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.

J Clin Invest 9 — Erber R et al Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.

FASEB J 18 2 — Welti JC et al Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis 15 4 — Tong RT et al Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors.

Cancer Res 64 11 — Shaheen RM et al Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res 61 4 — Winkler F et al Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

Cancer Cell 6 6 — Shojaei F et al Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Cascone T et al Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.

J Clin Invest 4 — Li JL et al DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res 71 18 — Casanovas O et al Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Cancer Cell 8 4 — Welti JC et al Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 30 10 — Cancer Res 70 24 — Huang D et al Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70 3 — Crawford Y et al PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment.

Cancer Cell 15 1 — di Tomaso E et al PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment. PLoS ONE 4 4 :e Kopetz S et al Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

J Clin Oncol 28 3 — Porta C et al Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients.

Oncology 84 2 — Johnson PJ et al Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31 28 — Llovet JM et al Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Motzer R Phase 3 trial of dovitinib vs sorafenib in patients with metastatic renal cell carcinoma after 1 prior VEGF pathway-targeted and 1 prior mTOR inhibitor therapy.

Presented at European cancer congress ; September 27—October 1, ; Amsterdam, The Netherlands. Abstract LBA Kalluri R, Zeisberg M Fibroblasts in cancer. Nat Rev Cancer 6 5 — Coussens LM, Werb Z Inflammation and cancer. De Palma M, Lewis CE Macrophage regulation of tumor responses to anticancer therapies.

Cancer Cell 23 3 — De Palma M, Naldini L Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Biochim Biophys Acta 1 — Bissell MJ, Radisky D Putting tumours in context. Nat Rev Cancer 1 1 — Joyce JA, Pollard JW Microenvironmental regulation of metastasis.

Nat Rev Cancer 9 4 — Ebos JM, Lee CR, Kerbel RS Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

Clin Cancer Res 15 16 — Shojaei F et al Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol 18 8 — McMillin DW, Negri JM, Mitsiades CS The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Nat Rev Drug Discov 12 3 — Reynolds AR Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose Response 8 3 — Nat Biotechnol 25 8 — Chung AS et al An interleukinmediated paracrine network promotes tumor resistance to anti-angiogenic therapy.

Nat Med 19 9 — Shaked Y et al Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

Lyden D et al Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7 11 — Cancer Cell 6 4 — Bailey AS et al Myeloid lineage progenitors give rise to vascular endothelium.

Proc Natl Acad Sci USA 35 — Yu JL et al Effect of p53 status on tumor response to antiangiogenic therapy. Yu JL et al Heterogeneous vascular dependence of tumor cell populations. Am J Pathol 4 — McIntyre A et al Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy.

Clin Cancer Res 18 11 — Nardo G et al Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization.

Cancer Res 71 12 — Hu YL et al Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res 72 7 — Rapisarda A, Melillo G Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia.

Nat Rev Clin Oncol 9 7 — Xu J et al Colorectal cancer cells refractory to anti-VEGF treatment are vulnerable to glycolytic blockade due to persistent impairment of mitochondria.

Mol Cancer Ther 12 5 — Cancer Res 62 7 — Dome B et al Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol 1 :1— Donnem T et al Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?

Cancer Med 2 4 — Ribatti D et al Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusceptive microvascular growth in primary melanoma. Oncol Rep 14 1 — Nico B et al Intussusceptive microvascular growth in human glioma.

Clin Exp Med 10 2 — Straume O et al Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res 62 23 — Folberg R, Maniotis AJ Vasculogenic mimicry.

APMIS 7—8 — Wang R et al Glioblastoma stem-like cells give rise to tumour endothelium. Ricci-Vitiani L et al Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Cheng L et al Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth.

Cell 1 — Kilarski WW et al Biomechanical regulation of blood vessel growth during tissue vascularization. Nat Med 15 6 — Cancer Res 71 1 — de Groot JF et al Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.

Neuro Oncol 12 3 — Pezzella F et al Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 5 — Yousem SA Peripheral squamous cell carcinoma of lung: patterns of growth with particular focus on airspace filling.

Hum Pathol 40 6 — Dome B et al Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance. J Pathol 3 — Sardari Nia P et al Distinct angiogenic and non-angiogenic growth patterns of lung metastases from renal cell carcinoma.

Histopathology 51 3 — Pezzella F et al Angiogenesis in primary lung cancer and lung secondaries. Eur J Cancer 32A 14 — Pezzella F et al Evidence for novel non-angiogenic pathway in breast-cancer metastasis. Breast cancer progression working party.

Vermeulen PB et al Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia.

Stessels F et al Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia.

Br J Cancer 90 7 — PLoS ONE 4 6 :e Leenders WP et al Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.

Clin Cancer Res 10 18 Pt 1 — Rubenstein JL et al Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2 4 — Paez-Ribes M et al Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Cancer Cell 15 3 — Winkler F et al Imaging glioma cell invasion in vivo reveals mechanisms of dissemination and peritumoral angiogenesis.

Glia 57 12 — Keunen O et al Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 9 — Cooke VG et al Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.

Sennino B et al Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2 3 — Cancer Cell 22 1 — Ebos JM et al Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Singh M et al Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J Pathol 4 — Chung AS et al Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. Blagoev KB et al Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma.

Cell Rep 3 2 — Powles T et al A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer. Ann Oncol 24 8 — Sharpe K, et al.

Miles D et al Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. Norden AD et al Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Neurology 70 10 — Ellis LM, Reardon DA Cancer: the nuances of therapy. Loges S et al Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Fan F et al Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration.

Br J Cancer 8 — Hammers HJ et al Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.

Mol Cancer Ther 9 6 — Ebos JM et al Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.

Proc Natl Acad Sci USA 43 — Zhu XD et al Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukinb in mouse models. Angiogenesis 16 4 — Xian X et al Pericytes limit tumor cell metastasis.

J Clin Invest 3 — Anderberg C et al Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. Lee S et al Autocrine VEGF signaling is required for vascular homeostasis. Cell 4 — Gabrilovich DI et al Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.

Nat Med 2 10 — Stockmann C et al Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Oosthuyse B et al Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.

Nat Genet 28 2 — Greenberg JI et al A role for VEGF as a negative regulator of pericyte function and vessel maturation. Wedam SB et al Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.

J Clin Oncol 24 5 — Fan F et al Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 24 16 — Ann Pathol 23 4 — Guo P et al Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth in vivo.

Cancer Res 63 15 — Spannuth WA et al Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer 5 — Wey JS et al Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines.

Cancer 2 — Barr MP, Bouchier-Hayes DJ, Harmey JJ Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia. Int J Oncol 32 1 — Hodivala-Dilke KM, Reynolds AR, Reynolds LE Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res 1 — Koch S et al Signal transduction by vascular endothelial growth factor receptors.

Biochem J 2 — Raimondi C, Ruhrberg C Neuropilin signalling in vessels, neurons and tumours. Semin Cell Dev Biol 24 3 — Tugues S et al Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Van de Veire S et al Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.

Bais C et al PlGF blockade does not inhibit angiogenesis during primary tumor growth. Pan Q et al Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth.

Cancer Cell 11 1 — Jiang T et al CD is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood 11 — Carmeliet P, Jain RK Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10 6 — Rathmell WK, Chen S VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.

Expert Rev Anticancer Ther 8 1 — Langenkamp E, Molema G Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer. Luzzi KJ et al Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases.

Am J Pathol 3 — Van den Eynden GG et al The histological growth pattern of colorectal cancer liver metastases has prognostic value. Clin Exp Metastasis 29 6 — Van den Eynden GG et al The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications.

Cancer Res 73 7 — Yap TA et al Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 4 ps Turner NC, Reis-Filho JS Genetic heterogeneity and cancer drug resistance. Lancet Oncol 13 4 :e—e Guerin E et al A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.

Cancer Res 73 9 — Shojaei F et al Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci USA 7 — A cancer needs a good blood supply to provide itself with food and oxygen and to remove waste products.

When it has reached 1 to 2 mm across, a tumour needs to grow its own blood vessels in order to continue to get bigger. Angiogenesis means the growth of new blood vessels. So anti angiogenic drugs are treatments that stop tumours from growing their own blood vessels.

If the drug is able to stop a cancer from growing blood vessels, it might slow the growth of the cancer or sometimes shrink it. Some cancer cells make a protein called vascular endothelial growth factor VEGF.

The VEGF protein attaches to receptors on cells that line the walls of blood vessels within the tumour. The cells are called endothelial cells. This triggers the blood vessels to grow so the cancer can then grow. Some drugs block vascular endothelial growth factor VEGF from attaching to the receptors on the cells that line the blood vessels.

This stops the blood vessels from growing. An example of a drug that blocks VEGF is bevacizumab Avastin. Bevacizumab is also a monoclonal antibody.

It is a treatment for several different types of cancer. Other examples include:. Some drugs stop the VEGF receptors from sending growth signals into the blood vessel cells.

These treatments are also called cancer growth blockers or tyrosine kinase inhibitors TKIs.

Antiangiogenesis therapies emerged as Anti-angiogenesis therapies for angiogenic diseases advancements in cancer treatment with yherapies FDA approval of bevacizumab Avastin to treat Female performance supplements Anti-angiogenesis therapies for angiogenic diseases cancer in combination with 5-fluorouracil 5-FU. Bevacizumab is a humanized monoclonal antibody against Antu-angiogenesis endothelial growth factor Therapids. This strategy of stopping tumor growth and metastasis by blocking tumor angiogenesis was pioneered by Judah Folkman, MD, and his colleagues almost four decades ago. A tumor requires and stimulates persistent angiogenesis to supply oxygen and nutrients for its survival and growth and to form a route for tumor cell egress. Antiangiogenesis therapy inhibits tumor growth and restrains metastasis by cutting the fuel supply and destroying the circulating pathway for the tumor cells by blocking tumor angiogenesis. Anti-angiogenesis therapies for angiogenic diseases Anti-angiogenesis therapy, disease promising Brown rice side dishes against therapis progression, is limited by drug-resistance, which could be attributed to changes within the tumor microenvironment. Theraapies have increasingly shown that combining anti-angiogenesis drugs with immunotherapy Anti-angiogenesis therapies for angiogenic diseases inhibits tumor growth and Antioxidant-Rich Healthy Living. Combination of anti-angiogenesis therapy ffor immunotherapy are disease Anti-angiogenesis therapies for angiogenic diseases options among solid Non-GMO cleaning supplies, such as Anti-angiogenesis therapies for angiogenic diseases cell lung cancer, hepatic cell carcinoma, and renal cell carcinoma. However, this combination has achieved an unsatisfactory effect among some tumors, such as breast cancer, glioblastoma, and pancreatic ductal adenocarcinoma. Therefore, resistance to anti-angiogenesis agents, as well as a lack of biomarkers, remains a challenge. In this review, the current anti-angiogenesis therapies and corresponding drug-resistance, the relationship between tumor microenvironment and immunotherapy, and the latest progress on the combination of both therapeutic modalities are discussed. The aim of this review is to discuss whether the combination of anti-angiogenesis therapy and immunotherapy can exert synergistic antitumor effects, which can provide a basis to exploring new targets and developing more advanced strategies.

Author: Moogular

5 thoughts on “Anti-angiogenesis therapies for angiogenic diseases

Leave a comment

Yours email will be published. Important fields a marked *

Design by ThemesDNA.com